Precision Biosciences INC Schedule 13G passive stakes

Empery Asset Management, LP and Ryan M. Lane have filed a Schedule 13G, reporting beneficial ownership of 4.99% of Precision BioSciences, Inc. common stock.

Lynx1 Capital Management LP and Weston Nichols have jointly filed a Schedule 13G, reporting beneficial ownership of 5.4% of Precision BioSciences Inc. common stock.

Empery Asset Management, LP and Ryan M. Lane have reported a beneficial ownership of 7.63% in Precision BioSciences, Inc. common stock as of March 31, 2026.

Lynx1 Capital Management LP and Weston Nichols have reported a 4.1% beneficial ownership stake in Precision BioSciences Inc., totaling 993,913 shares of common stock.

Octagon Capital Advisors LP, along with its Master Fund and Ting Jia, reported a 9.99% beneficial ownership stake in Precision BioSciences, Inc. as of December 31, 2025.

Aberdeen Group plc and abrdn Inc. have reported a shared beneficial ownership of 8.88% in Precision Biosciences Inc. as of December 31, 2025.

Empery Asset Management, LP and Ryan M. Lane have reported a 9.99% beneficial ownership stake in Precision BioSciences, Inc., including shares from warrants, as of December 31, 2025.

Lynx1 Capital Management LP and Weston Nichols have disclosed an 8.8% beneficial ownership stake in Precision BioSciences Inc., totaling 1,042,596 shares.

Readout Capital and affiliated entities, including Matthew Smith, have disclosed a significant beneficial ownership stake of up to 9.4% in Precision BioSciences Inc.

Bleichroeder LP, Bleichroeder Holdings LLC, and Andrew Gundlach have disclosed a beneficial ownership of 9.69% in Precision BioSciences Inc.'s common shares.

Aquilo Capital and its affiliates have reported a complete divestment of their beneficial ownership in Precision Biosciences Inc., reducing their stake to 0.0%.

Novartis Pharma AG and its parent Novartis AG have disclosed a 3.7% passive beneficial ownership stake in Precision Biosciences Inc. through an amended Schedule 13G filing.

Tang Capital Management, LLC and affiliated entities, including Kevin Tang, have disclosed a combined 6.4% beneficial ownership stake in Precision BioSciences, Inc. as of March 31, 2025, held for passive investment purposes.

Highbridge Capital Management, LLC has filed an amended Schedule 13G, reporting beneficial ownership of 3.7% of Precision BioSciences Inc.'s common stock, primarily through warrants.

A group of investment entities and individuals, including Readout Capital and Matthew Smith, have disclosed beneficial ownership of up to 8.9% of Precision BioSciences Inc.'s common stock.

Benjamin Weinstein has reported a beneficial ownership of 5.2% of Precision Biosciences Inc.'s common stock, totaling 395,489 shares, as of March 18, 2025.

Aquilo Capital, L.P., Aquilo Capital Management, LLC, and Marc Schneidman have filed an amended Schedule 13G, disclosing beneficial ownership of up to 9.9% of Precision Biosciences Inc.'s common stock.

Janus Henderson Group plc has filed an amended Schedule 13G, indicating it holds no beneficial ownership in Precision BioSciences, Inc. as of December 31, 2024.

Lynx1 Capital Management LP and Weston Nichols have reported a beneficial ownership of 9.99% in Precision BioSciences Inc., holding 766,051 shares of common stock as of December 31, 2024.

Novartis Pharma AG and its parent company Novartis AG have filed an amended Schedule 13G, confirming their continued beneficial ownership of 5.4% of Precision Biosciences Inc.'s common stock as of December 31, 2024.